• Alexis RIDEAU, Deputy Chief Executive Officer of DEINOVE since May 2020, is now the Chief Executive Officer of the Company.
  • Charles WOLER, who acted as Interim-Chief Executive Officer of DEINOVE, remains Chairman of its Board of Directors, a function he has held since 2017.

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company pioneering the exploration and exploitation of bacterial biodiversity to address the urgent and global challenge of antimicrobial resistance, announces the appointment of Alexis RIDEAU as Chief Executive Officer, with effect from January 8, 2021.

“The Board of Directors and I confirm our full confidence in Alexis. Since his entry in the company, he has driven the momentum we were expecting from his appointment as Deputy Chief Executive Officer of DEINOVE. In just a few months, he has strengthened the Company's positioning in the antimicrobial field and worked to promote DEINOVE's scientific capabilities to its current and future partners. He is now the Chief Executive Officer of this biotech company with high potential in the race against antimicrobial resistance”, commented Charles WOLER, Chairman of DEINOVE.

“I would like to thank Charles WOLER and all the members of the Board of Directors for renewing their confidence in me. Since last May, I have been working on the operating transformation to ensure that it becomes a leading driver of innovation in the exploration and exploitation of microbial biodiversity. The energy and determination of DEINOVE's teams made it possible for me to take up my position under optimal conditions, despite the context of the COVID-19 pandemic. Together we are fully committed to developing DEINOVE as a major player in the generation of new antimicrobials”, added Alexis RIDEAU, CEO of DEINOVE.